Clinical Trials Browser

Lymphadenopathy, Anemia, Communicable Diseases, Fever, Lymphocytosis, Thrombocytopenia, Weight Loss, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Neoplasms, Second Primary

NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Phase 2 Completed

16 enrolled 11 charts

Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

NCT01392989 2019-05-07

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Phase 2 Completed

44 enrolled 13 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neural Tube Defects

NCT02761642 2018-08-24

A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

Phase 2 Completed

200 enrolled 13 charts

Classical hematology

Anemia

NCT00987480 2018-07-10

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

Phase 2 Completed

45 enrolled 12 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Anemia, Aplastic, Leukemia, Myelodysplastic Syndromes

NCT00481624 2018-03-05

Procrit

Phase 2 Withdrawn

Classical hematology

Anemia

NCT00416624 2017-02-10

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

Phase 2 Completed

239 enrolled 23 charts

Classical hematologyDermatologicLymphoidOther hematologic neoplasmOther neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Anemia, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Mycosis Fungoides, Precancerous Conditions, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell

NCT00031980 2016-07-06

Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer

Phase 2 Completed

30 enrolled

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Neutropenia, Thrombocytopenia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Large Granular Lymphocytic

NCT00077311 2016-06-30

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

160 enrolled

Classical hematologyThoracic

Adenocarcinoma of Lung, Anemia, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neutropenia, Drug-Related Side Effects and Adverse Reactions

NCT01116479 2014-11-05

HaemOPtimal

Phase 2 Terminated

180 enrolled

Classical hematology

Anemia, Neoplasms

NCT01691040 2014-06-26

Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer

Phase 2 Completed

12 enrolled

Classical hematologyLymphoidPlasma cell

Anemia, Lymphoma, Multiple Myeloma, Neoplasms

NCT00401544 2014-01-29

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Phase 2 Completed

243 enrolled 26 charts

Classical hematology

Anemia, Neoplasms

NCT00989092 2014-01-29

Darbepoetin Alfa and Anemia of Cancer

Phase 2 Terminated

287 enrolled 21 charts

Classical hematology

Anemia, Carcinoma, Neoplasms

NCT00386152 2013-07-19

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Phase 2 Terminated

235 enrolled 13 charts

Classical hematology

Anemia, Neoplasms

NCT00072059 2013-07-18

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00053001 2013-06-26

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Phase 2 Completed

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00004215 2013-06-19

Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia

Phase 2 Completed

Classical hematologyOther hematologic neoplasm

Anemia, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Neutropenia, Thrombocytopenia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00144131 2013-05-24

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

Phase 2 Completed

750 enrolled

Classical hematology

Anemia, Neoplasms

NCT00035607 2013-05-13

Chemotherapy Related Anemia

Phase 2 Completed

120 enrolled

Classical hematology

Anemia

NCT00111462 2013-05-08

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00540696 2013-04-26

Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa

Phase 2 Completed

300 enrolled

Classical hematology

Anemia

NCT00272662 2012-12-21

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

Phase 2 Completed

60 enrolled

Classical hematology

Anemia, Neoplasms

NCT00301912 2012-10-02

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase 2 Withdrawn

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Blast Crisis, Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00359840 2012-08-31

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

Phase 2 Completed

120 enrolled

Classical hematology

Anemia

NCT00004914 2012-06-06

Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue

Phase 2 Completed

Classical hematology

Anemia, Fatigue

NCT00210600 2011-06-10

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Phase 2 Completed

186 enrolled

Classical hematology

Anemia

NCT00210834 2011-06-10

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Phase 2 Completed

310 enrolled

Classical hematology

Anemia

NCT00337948 2011-06-10

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Phase 2 Completed

129 enrolled

Classical hematology

Anemia, Neoplasms

NCT00338416 2011-06-10

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Phase 2 Completed

115 enrolled

Classical hematology

Anemia, Neoplasms

NCT00269984 2011-06-08

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

Phase 2 Completed

56 enrolled

Classical hematology

Anemia, Neoplasms

NCT00266617 2011-05-18

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy

Phase 2 Completed

86 enrolled

Classical hematology

Anemia, Neoplasms

NCT00269997 2011-05-18

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Phase 2 Completed

72 enrolled

Classical hematology

Anemia, Neoplasms

NCT00270049 2011-05-18

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

Phase 2 Completed

195 enrolled

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Leukemia, Lymphoid, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

Newton

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

PTCA199-4

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

MK-7962-012

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

FCM

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

Procrit

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

HaemOPtimal

Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Darbepoetin Alfa and Anemia of Cancer

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

Chemotherapy Related Anemia

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia